GENISIF-DS21: Advancing Preclinical Research in Down Syndrome
- CIPHE
- Sep 17, 2025
- 1 min read
The GENISIF-DS21 project (Genetics of Peripheral and Neuro-Inflammation in Down Syndrome) has been selected under the ANR AAPG 2025 call!
As a partner in this project, CIPHE will study the impact of perinatal inflammation and early infections on physiology and cognitive functions in Down syndrome mouse models.
Key objectives include:
Assessing how inflammatory challenges (IL1β, poly(I:C)) affect peripheral and brain inflammation, memory, and learning.
Investigating the intrinsic role of immune cells in the excessive inflammatory activation observed in Down syndrome, using hematopoietic chimeras.
This work aims to provide new insights into the links between inflammation, cognitive deficits, and neurodevelopmental disorders, opening potential therapeutic perspectives.
With GENISIF-DS21, CIPHE strengthens its commitment to preclinical research at the interface of immunology and neurobiology, advancing understanding and treatment of complex disorders.
